MERCK & CO INC

Discover how Merck & Co. and Kelun‑Biotech are leveraging AI-driven trials and strategic pricing to capture U.S. and Chinese oncology markets amid bullish equity trends.

Merck’s latest 8‑K shows a promising lung‑cancer trial and a new debt deal that fuels R&D and boosts investor confidence—highlighting the firm’s strategy to win value‑based pricing and expand access amid a competitive oncology landscape.

Merck’s May 15 shareholders meeting and Q3 earnings reveal the company’s oncology focus, patent‑cliff strategy and M&A plans for growth.

Merck’s new TROP‑2 antibody‑drug conjugate shows survival gains in endometrial and cervical cancers, while a Terns Pharma acquisition expands its CML pipeline and boosts oncology assets.

Merck’s 13‑F HR filing reveals its stake in early‑stage biotech, spotlighting Alector’s Alzheimer’s Phase‑III success and Carisma’s CAR‑T trials, while the company’s life‑science guidance boost drives modest stock gains.

Merck’s acquisition of Terns Pharmaceuticals clears a key antitrust hurdle, potentially boosting its specialty drug portfolio and valuation while navigating Medicare reimbursement and breakthrough therapy benefits.

Merck’s share dip amid a tech rally shows pharma’s slower momentum; insights on its vaccine tie‑ups, R&D spend and precision‑medicine prospects guide investors.

Merck’s MRK stock faces a temporary XETR outage, halting German trading—investors should monitor the pause and its impact on dividend‑focused ETFs.

Merck’s tariff‑exemption deal, KEYTRUDA® fast‑track expansion and helium‑supply vigilance reveal how the pharma giant balances U.S. pricing, oncology innovation and global supply risks.

Merck’s strategic moves—from long‑term HPV vaccine data to a Keytruda‑AI combo—aim to secure premium pricing, fend off generics, and grow precision oncology revenue.